Understand the source comparison
ARA-290 Research Review: Clinical Evidence Comparison
Sarcoidosis-associated SFN (n=28, 2014) 4mg ARA-290 SC 3×/week for 28 days Change in neuropathic pain score (NPS) Mean NPS reduction 2.2 points vs placebo (p=0.02); IENFD increased Demonstrated nerve regeneration, not just symptom masking. Rare in neuropathy t
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Sarcoidosis-associated SFN (n=28, 2014)
- 4mg ARA-290 SC 3×/week for 28 days
- Change in neuropathic pain score (NPS)
- Mean NPS reduction 2.2 points vs placebo (p=0.02); IENFD increased
- Demonstrated nerve regeneration, not just symptom masking. Rare in neuropathy trials
- Type 2 diabetes with metabolic syndrome (n=80, 2015)
- 1mg, 3mg, or 10mg ARA-290 SC 3×/week for 28 weeks
- Insulin sensitivity (clamp-measured)
- 18% improvement at 10mg dose (p=0.04); visceral fat reduced 12%
- Addresses tissue-level metabolic dysfunction beyond glucose control
- Diabetic peripheral neuropathy (n=40, 2017)
- 3mg ARA-290 SC 3×/week for 12 weeks
- Change in corneal nerve fiber length (CNFL)
- CNFL increased 8.3% vs 1.2% placebo (p=0.03)
- Corneal confocal microscopy detected small-fiber regeneration earlier than symptom improvement
- Preclinical (rat ischemia-reperfusion)
- 10mcg/kg ARA-290 IV within 6h of injury
- Tubular damage markers, GFR recovery
- 40% reduction in KIM-1, 50% faster GFR recovery vs saline
- Suggests therapeutic window for acute kidney injury. Human trials needed